Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients

  • Urvay, Semiha Elmaci (Acibadem Hospitals Group) ;
  • Yucel, Birsen (Cumhuriyet Univercity Medical Oncology Deparment) ;
  • Erdis, Eda (Cumhuriyet Univercity Medical Oncology Deparment) ;
  • Turan, Nedim (Cumhuriyet Univercity Medical Oncology Deparment)
  • Published : 2016.10.01


Aim: The objective of this study is to investigate prognostic factors affecting survival of patients undergoing concurrent or sequential chemoradiotherapy (CRT) for stage III non-small-cell lung cancer (NSCL). Methods and materials: We retrospectively reviewed the clinical records of 148 patients with advanced, inoperable stage III NSCLC, who were treated between 2007 and 2015. Results: The median survival was found to be 19 months and 3-year overall survival was 27%. Age (<65 vs ${\geq}65years$, p=0.026), stage (IIIA vs IIIB, p=0.033), dose of radiotherapy (RT) (<60 vs ${\geq}60Gy$, p=0.024) and treatment method (sequential chemotherapy+RT vs concurrent CRT, p=0.023) were found to be factors affecting survival in univariate analyses. Gender, histological subtype, weight loss during CRT, performance status, induction/consolidation chemotherapy and presence of comorbidities did not affect survival (p>0.050). Conclusion: Young age, stage IIIA, radiotherapy dose and concurrent chemoradiotherapy may positively affect survival in stage III NSCL cases.


Non-small lung cancer;prognostic factors;survival


  1. Blanchon F, Grivaux M, Asselain B, et al (2015). 4-year mortality in patients with non-small cell lung cancer: Development and validation of a prognostic index. Lancet Oncol, 16, 187-99.
  2. Abbasi S, Badheeb A (2011). Prognostic factors in advanced non-small-cell lung cancer patients:patient characteristics and type of chemotherapy. lung Cancer Int, 2011, 1-4.
  3. Arslan D, Bozcuk H, Gunduz S, et al (2014). Survival Results and Prognostic Factors in T4 NO-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system. Asian Pac J Cancer Prev, 15, 2465-72
  4. Bradley JD, Paulus R, Komaki R, et al (2015). Standart-dose versus high dose conformal radiotherapy with concurrent and consolidaiton carboplatine plus paclitaxel with or without cetuximab for patients with stage IIIA or III B non-small cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol, 16, 187-99.
  5. Capewell S, Sudlow MF (1990). Performance and prognosis in patients with lung cancer. Thorax, 45, 951-6.
  6. Coate LE, Massey C, Hope A, et al (2011). Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stageIII non-small cell lung cancer. J Thorac Oncol, 6, 537-44.
  7. Auperin A, Le Pechoux C, Rolland E, et al (2010). Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J C Oncol, 28, 2181-90.
  8. Birim O, Kappetein AP, Van Klaveren RJ, et al (2006). Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol, 32, 12-23.
  9. Curran WJ-Jr, Paulus R, Langer CJ, et al (2011).Sequential vs.Concurrent Chemoradiation for stage III non-small cell lung cancer: randomised phase III trial RTOG 9410. J Natl Cancer Inst, 103, 1452-60.
  10. Dillman RO, Herndon J, Seagren SL,et al (1996). Improved survival in stage III non-small-cell lung cancer: seven year follow up of cancer and leukemia group B (CALGB)8433 trial. J Natl Cancer Inst, 88, 1210-5
  11. Feld R, Borges M, Giner V, et al (1994). Prognostic factors in non-small cell lung cancer. Lung Cancer Nov, 3, 19-23.
  12. Fentiman IS, Tirelli U, Monfardini S, et al (1990). Cancer inthe elderly: why so badly treated? Lancet, 335, 1020-2.
  13. Finkelstein D, Ettinger DS, Ruckdeschel JC (1986). Long-Term Survivors in Metastatic Non-Small-Cell Lung Cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol, 4, 702-9.
  14. Furuse K, Fukuoka M, Kawahara M, et al (1999). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol, 17, 2692-9.
  15. Furuse K, Hosoe S, Masuda N, et al (2000). Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy and chemotherapy (abstract). Proc Am Soc Clin Oncol, 29, 90-6.
  16. Gaspar LE, Chansky K, Albain KS et al (2005). Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol, 23, 2955-61.
  17. Gregory MM, Videtic Larry W, Stitt A, et al (2003). continued cigarette smoking by patients receiving Cconcurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol, 21, 1544-9.
  18. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute.
  19. Langer C, Scott C, Byhardt R, et al (2000) Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LA-NSCLC). Lung Cancer, 29, 104-10.
  20. Movsas B, Scott C, Sause W, et al (1999) The benefit of treatment intensification is age and histology-dependent in patients with locally advanced nonsmall cell lung cancer (nsclc): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys, 45, 1143-9.
  21. Mutlu H, Buyukcelik A, Erden A, et al (2013). Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev, 14, 3743-6.
  22. O'Rourke N, Roque I Figuls M, Farre Bernado N, et al (2010). Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev, 16, CD002140.
  23. Perez CA, Pajak TF, Rubin P, et al (1987). Long term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. report by the radiation therapy oncology group. Cancer, 59, 1874-80.<1874::AID-CNCR2820591106>3.0.CO;2-Z
  24. Piccirillo JF, Tierney RM, Costas I, et al (2004). Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA, 291, 2441-7.
  25. Sause W, Kolesar P, Taylor S IV, et al (2000).Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group and southwest oncology group. Chest, 117, 358-64.
  26. Siegel RL, Miller KD, Jemal A. Cancer Statics, 2015. CA Cancer J Clin, 65, 5-29
  27. Tsujino K, Kurata T, Yamamoto S, et al (2013). Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer?A pooled analyses of the literature. J Thorac Oncol, 8, 1181-9.
  28. Van Baardwijk A, Wanders S, Boersma L, et al (2010). Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol, 28, 1380-6.
  29. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al (1997). Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg, 36, 1441-50.
  30. Vokes EE, Herndon JE, Kelly MJ, et al (2007). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer. cancer and leukemia group B. J Clin Oncol, 25, 1698-704.
  31. Wolf M, Holle R, Gropp C, et al (1991). Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer, 63, 986-92.
  32. Wahbah M, Boroumand N, Castro C, et al (2007).Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol, 11, 89-96.